Free Trial
→ Reagan’s former tech advisor sharing bombshell announcement (From Banyan Hill Publishing) (Ad)tc pixel

Faron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Below 50-Day Moving Average - Here's What Happened

Written by MarketBeat
Updated September 12, 2025
Faron Pharmaceuticals Oy logo with Medical background

Key Points

  • Faron Pharmaceuticals Oy shares fell below their 50-day moving average of GBX 207.59, trading as low as GBX 190 during Monday's trading session.
  • The company's stock is currently down 2.1%, with a market capitalization of £213.83 million and a PE ratio of -707.41.
  • Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for significant unmet medical needs, including its investigative immunotherapy, Clevegen (bexmarilimab).
  • Five stocks to consider instead of Faron Pharmaceuticals Oy.

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 207.59 ($2.82) and traded as low as GBX 190 ($2.58). Faron Pharmaceuticals Oy shares last traded at GBX 198.80 ($2.70), with a volume of 10,378 shares trading hands.

Faron Pharmaceuticals Oy Stock Performance

The stock has a market cap of £212.71 million, a PE ratio of -703.70 and a beta of 0.36. The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The business has a 50 day moving average price of GBX 206.15 and a two-hundred day moving average price of GBX 207.31.

About Faron Pharmaceuticals Oy

(Get Free Report)

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

See Also

Should You Invest $1,000 in Faron Pharmaceuticals Oy Right Now?

Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.

While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover
10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.